StockDuty ← Dashboard Sep 17, 2026 05:54 AM ET
CatalystFDA/Bio

Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

Phase III CELESTIMO data show significant progression-free survival improvement in follicular lymphoma.

What changed
Phase III CELESTIMO data show significant progression-free survival improvement in follicular lymphoma.
Why it matters
Phase III CELESTIMO data show significant progression-free survival improvement in follicular lymphoma. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →